Brainstorm readies late-stage NurOwn study in ALS; shares up 4%

|By:, SA News Editor

Thinly traded nano cap Brainstorm Therapeutics (BCLI +3.7%) is up on a 12x surge in volume in response to its announcement it has reached general agreement with the FDA on the key elements of a Phase 3 study assessing NurOwn in patients with amyotrophic lateral sclerosis (ALS). The randomized, double-blind, placebo-controlled trial should commence in Q2 2017.

The company also announces plans to submit an application in Israel that will allow patient access to NurOwn.

NurOwn cells are mesenchymal stem cells that have been induced, via the company's proprietary methods, to secrete a variety of neurotrophic factors.

Subscribe for full text news in your inbox